Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Employees - 7,
CEO - Mr. Nathan Jacob Givoni,
Sector - Healthcare,
Country - AU,
Market Cap - 21.52M
| Ticker | GELS |
| Index | - |
| Curent Price | 2.28 |
| Change | -1.72% |
| Market Cap | 21.52M |
| Average Volume | 1.54M |
| Income | - |
| Sales | - |
| Book Value/Share | 1.07 |
| Cash/Share | 0.00 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 20 |
| Moving Avg 20days | 82.16% |
| Moving Avg 50days | 64.57% |
| Moving Avg 200days | 14.61% |
| Shares Outstanding | 9.44M |
| Earnings Date | - |
| Inst. Ownership | 0.86% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 2.13 |
| Price/Cash | 1076.16 |
| Price/FCF | - |
| Quick Ratio | 0.08 |
| Current Ratio | 0.08 |
| Debt/Equity | 0.25 |
| Return on Assets | - |
| Return on Equity | - |
| Return on Investment | - |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 66.92 |
| BETA(β) | - |
| From 52week Low | 196.07% |
| From 52week High | -58.55% |
| EPS | - |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | -74.90% |
| EPS Y/Y | - |
| Sales Y/Y | - |
| EPS Q/Q | - |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.35 |
| Perf Week | 146.22% |
| Perf Month | 105.41% |
| Perf Quarter | -19.15% |
| Perf Year | - |
| Perf YTD | -1.72% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer